Brief: Mirum Pharmaceuticals Q3 Operating Expenses USD 103.061 Million
12/11/2024 13:00
Nov 12 (Reuters) - Mirum Pharmaceuticals Q3 operating income USD -12.684 million. * Q3 net income USD -14.235 million * Q3 product sales USD 90.302 million * Q3 basic EPS USD -0.3
Recent news on Mirum Pharmaceuticals
See all newsMirum Pharmaceuticals Q3 net product sales surge, outlook raised
Brief: Mirum Pharmaceuticals Announces Positive Results From Cohort 2 Of The Pivotal Progress Study Of Atebrioz™ (Zilurgisertib) In Pediatric Patients Aged 6 To <12 Years With Fibrodysplasia Ossificans Progressiva
Mirum climbs on positive late-stage trial results for liver disease drug
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX